Latham & Watkins Advises on ArriVent’s US$75 Million Common Stock Offering and Pre-Funded Warrants

ArriVent BioPharma, Inc. (ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, has announced the pricing of an underwritten public offering of 2,482,692 shares of its common stock at a price to the public of US$19.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,363,469 shares of its common stock at a price to the public of US$19.4999, which represents the per share public offering price for the shares of common stock less US$0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to ArriVent from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately US$75 million. In addition, ArriVent has granted the underwriters a 30-day option to purchase up to an additional 576,923 shares of its common stock on the same terms and conditions. All of the securities are being offered by ArriVent. This offering is expected to close on or about July 3, 2025, subject to the satisfaction of customary closing conditions.

Latham & Watkins advised the underwriters in the offering with a capital markets team led by New York partners Nathan Ajiashvili and Alison Haggerty, with associates Sandy Kugbei and Jie Lin Nai.